VERAXA Biotech AG (NASDAQ: VRXA) has announced a significant milestone in its oncology pipeline, as its VXA-222 bispecific antibody-drug conjugate (bsADC) program has moved beyond the discovery phase into the next stage of development. This progress follows the successful completion of the discovery phase with OmniAb, which delivered a portfolio of therapeutic antibody binders. VERAXA is now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary antibody engineering, linker, and conjugation technologies, making it one of its more advanced development programs. The company's ability to integrate these technologies underscores its commitment to developing novel cancer therapies that target difficult-to-treat malignancies.
In parallel with the development milestone, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, ensuring long-term exclusivity for its innovations.
This strategic expansion of IP is crucial for VERAXA as it continues to build a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats. The company is focused on addressing cancers that have historically been resistant to conventional treatments, and its growing patent portfolio protects the proprietary technologies that underpin these efforts.
The announcement marks the successful completion of the discovery portion of VERAXA's collaboration with OmniAb, which began in May 2025 (https://nnw.fm/nIprz). With this phase complete, VERAXA will now concentrate on constructing the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary technology. This approach is designed to optimize the efficacy and safety of the resulting therapy.
For investors and stakeholders, the advancement of VXA-222 and the simultaneous expansion of VERAXA's intellectual property are positive indicators of the company's progress. The company's ability to move programs forward while securing its technology position is essential in the competitive field of oncology drug development. As VERAXA continues to execute on its strategy, it is well-positioned to deliver innovative treatments that could have a meaningful impact on patient outcomes.
For the latest news and updates on VERAXA, visit the company's newsroom at https://nnw.fm/VRXA.
